Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPeat, R.-
dc.contributor.authorGecz, J.-
dc.contributor.authorFallon, J.-
dc.contributor.authorTarpey, P.-
dc.contributor.authorSmith, R.-
dc.contributor.authorFutreal, P.-
dc.contributor.authorStratton, M.-
dc.contributor.authorLamande, S.-
dc.contributor.authorYang, N.-
dc.contributor.authorNorth, K.-
dc.identifier.citationNeuromuscular Disorders, 2008; 18(8):606-609-
dc.descriptionCopyright © 2008 Elsevier B.V. All rights reserved.-
dc.description.abstractBiglycan has been considered a good candidate for neuromuscular disease based on direct interactions with collagen VI and α-dystroglycan, both of which are linked with congenital muscular dystrophy (CMD). We screened 83 patients with CMD and other neuromuscular disorders and six controls for mutations and variations in the biglycan sequence. We identified a number of novel sequence variations. After family analysis and control screening we found that none of these polymorphisms were disease-causing mutations. Thus mutations in biglycan are not a common cause of neuromuscular disorders in our cohort.-
dc.description.statementofresponsibilityRachel A. Peat, Jozef Gécz, Justin R. Fallon, Patrick S. Tarpey, Raffaella Smith, Andrew Futreal, Michael R. Stratton, Shireen R. Lamandé, Nan Yang and Kathryn N. North-
dc.publisherPergamon-Elsevier Science Ltd-
dc.subjectCongenital muscular dystrophy-
dc.subjectCollagen VI-
dc.titleExclusion of biglycan mutations in a cohort of patients with neuromuscular disorders-
dc.typeJournal article-
dc.identifier.orcidGecz, J. [0000-0002-7884-6861]-
Appears in Collections:Aurora harvest
Paediatrics publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.